Related Experiment Videos
Long-term results (from 5 to 7 years) with the Hancock S-G-P bioprosthesis
Insights
The Hancock-SGP bioprosthesis demonstrates durability in heart valve replacement surgery. Long-term results show proper function, supporting its use in mitral and aortic positions.
Area of Science:
- Cardiovascular Surgery
- Bioprosthetic Heart Valves
Background:
- The Hancock-SGP bioprosthesis is a glutaraldehyde-preserved porcine valve used for heart valve replacement.
- Early clinical application and long-term outcomes are crucial for evaluating prosthetic device efficacy.
Purpose of the Study:
- To assess the long-term clinical results, complications, and survival rates of patients undergoing heart valve replacement with the Hancock-SGP bioprosthesis.
- To evaluate the hemodynamic performance and durability of the Hancock-SGP bioprosthesis in various valvular positions.
Main Methods:
- Retrospective analysis of 113 patients who received Hancock-SGP bioprosthetic heart valves between March 1970 and March 1972.
- Clinical reevaluation, hemodynamic assessment, and analysis of late mortality in 92 survivors with 5 to over 7 years of follow-up.
Main Results:
- Hospital mortality was 18.5%.
- In 92 survivors followed for 5-7+ years, prostheses functioned properly in both mitral and aortic positions.
- Hemodynamic reevaluation in 26 patients confirmed satisfactory prosthetic function.
Conclusions:
- The glutaraldehyde-preserved porcine valve (Hancock-SGP bioprosthesis) exhibits durability in long-term follow-up.
- The Hancock-SGP bioprosthesis is a viable option for heart valve replacement in any valvular position.
Abstract:
This communication is concerned with the long-term results of the first 113 patients who underwent single or multiple heart valve replacement with the Hancock-SGP bioprosthesis at the Department of Cardiovascular Surgery, University of Padova Medical School, in a two years period (March 1970-March 1972). Hospital mortality was 18.5%; of the 92 survivors, whose follow-up is now 5 to more than 7 years, the authors report the clinical reevaluation, the complications and the causes of late death. Hemodynamic reevaluation has been performed so far in 26 patients and the prostheses have shown to function properly both in the mitral and the aortic position. The data available to date indicate that the glutaraldehyde preserved porcine valve is durable and its use is warranted in any valvular position.